California Center for Psychedelic Therapy

What California Center for Psychedelic Therapy does

Psychedelic Science Institute (PSI), operating in California as Psychedelic Science Institute, LLC, is a clinical and research organization formed on July 1, 2025 through the merger of two predecessor entities — Pacific Neuroscience Institute's TRIP Center (established 2019 in Santa Monica) and the California Center for Psychedelic Therapy (established 2018 in Hollywood). PSI operates two TRIP Clinic locations in Los Angeles (Hollywood and Santa Monica) that deliver ketamine-assisted psychotherapy (KAP), transpersonal psychotherapy, psychiatric medication management, and psychedelic integration services to adult patients presenting with depression, treatment-resistant depression, anxiety disorders, PTSD, OCD, traumatic stress, bipolar disorder, and addiction.

The core clinical technology is intramuscular ketamine administration combined with structured preparation, supervised dosing, and integration therapy — a delivery method that the company cites as providing 98% bioavailability comparable to IV administration at lower cost and invasiveness. PSI also functions as an FDA-regulated clinical trial site, currently conducting or enrolling in 16 trials sponsored by biotech partners including atai Life Sciences (DMT for treatment-resistant depression), Usona Institute (Phase 3 psilocybin for major depressive disorder), Mind Medicine (MM120/LSD for generalized anxiety disorder), and Cybin, covering psilocybin, LSD, MDMA, and DMT compounds. To date the organization states it has supported 12,000+ ketamine-assisted psychotherapy sessions and has leadership with 30+ years of psychedelic clinical and research experience.

PSI operates as a cash-pay professional services practice; it does not accept insurance, provides superbills for potential out-of-network reimbursement, and offers sliding scale on select therapy services. Pricing is unit-based: KAP initial evaluation at $550, KAP sessions at $600, transpersonal psychotherapy at $250 per 50 minutes, psychiatric medication management at $300 per 30 minutes, and integration/consultation between $250 and $550 per hour, with a $150 deposit required to schedule. Telehealth is offered for intake, integration, and talk therapy; psychedelic dosing sessions require in-person attendance. Customer acquisition is primarily direct-to-consumer through website content, blog, newsletter, and patient self-referral, supplemented by a formal healthcare provider referral pathway.

Name

California Center for Psychedelic Therapy

Legal name

Psychedelic Science Institute, LLC

Website

https://psychedelictherapyca.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Psychedelic Science Institute (PSI) operates two TRIP Clinics in Los Angeles delivering cash-pay ketamine-assisted psychotherapy and serving as an FDA-regulated clinical trial site for psilocybin, LSD, and DMT sponsored by biotech partners, targeting adults with treatment-resistant mental health conditions.

Ownership category

akta.pro rank

Product category

Mental Health Services

NAICS

Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)

akta.pro secondary industry

Outpatient Substance Use Treatment Programs (IOP/PHP/OP) (HLAFACAF)

Keywords

• Psychedelic assisted therapy
• Ketamine assisted psychotherapy
• Mental health treatment
• Clinical research trials
• Psychedelic integration therapy

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

1. Ketamine-Assisted Psychotherapy Services: Fee-for-service model for ketamine-assisted psychotherapy including initial evaluation ($550), KAP sessions ($600), and maintenance treatments. Patients pay out-of-pocket; insurance is not accepted but superbills are provided for potential out-of-network reimbursement.
2. Psychotherapy and Medication Management: Individual psychotherapy sessions ($250 for 50-minute transpersonal psychotherapy with sliding scale options) and psychiatric medication management ($300 for 30 minutes).
3. Clinical Trial Research: PSI conducts FDA-regulated clinical trials sponsored by biotech partners including Atai Life Sciences, MindMed, Usona Institute, and Cybin. Trials are provided at no cost to qualifying participants, with compensation for travel and time.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

PSI operates TRIP Clinics in Santa Monica and Hollywood providing ketamine-assisted psychotherapy (KAP), psychedelic integration therapy, individual psychotherapy, and psychiatric medication management for adults with depression, trauma, anxiety, addiction, OCD, and bipolar disorder. The organization also conducts FDA-regulated Phase 3 clinical trials investigating psilocybin, LSD, and DMT for major depressive disorder, treatment-resistant depression, and generalized anxiety disorder.

Product overview

Psychedelic Science Institute (PSI) is a mental health organization formed in July 2025 through the merger of two pioneering entities: the Pacific Neuroscience Institute's TRIP Center (est. 2019) and the California Center for Psychedelic Therapy (est. 2018). PSI operates two TRIP Clinics in Santa Monica and Hollywood, Los Angeles, offering ketamine-assisted psychotherapy (KAP) as a primary service alongside psychedelic integration therapy, psychotherapy, and medication management. PSI also conducts multiple FDA-regulated clinical trials investigating psilocybin, LSD, and DMT for conditions including major depressive disorder, treatment-resistant depression, and generalized anxiety disorder. The organization has delivered over 12,000 ketamine-assisted psychotherapy sessions and completed 16 clinical trials. Services are grounded in evidence-based psychedelic medicine with a focus on neuroplasticity, preparation, supervised dosing, and integration protocols.

Differentiator

Problem solved

Functional benefit

Products and services

• Ketamine-Assisted Psychotherapy (KAP) A structured, supervised program combining sub-anesthetic doses of ketamine with psychotherapy for depression, trauma, or chronic pain. Delivered by licensed clinicians and includes preparation sessions, supervised dosing, and integration therapy. Typically an initial series of 8 KAP sessions over four weeks followed by maintenance sessions.
• Initial Evaluation for KAP 90-minute clinical evaluation session conducted prior to starting ketamine-assisted psychotherapy. Includes clinical assessment, eligibility screening, and treatment planning.
• Psychedelic Integration Therapy Integration therapy that helps patients process and synthesize experiences from psychedelic treatments into meaningful, lasting changes in daily life. Part of the structured therapeutic protocol surrounding KAP and clinical trial participation.
• Psychotherapy (Transpersonal) 50-minute individual transpersonal and general psychotherapy sessions with licensed mental health professionals, addressing various mental health conditions. Sliding scale options available.
• Psychiatric Medication Management 30-minute psychiatric medication management sessions handled on an individual basis with medications chosen based on best available evidence for clients needing pharmacological support.
• TRIP Clinic Hollywood Physical clinic location at 522 N. Larchmont Blvd., Los Angeles serving Hollywood and North Central Los Angeles. Provides ketamine-assisted psychotherapy, clinical trials (including MindMed LSD for GAD), psychedelic integration, and psychotherapy services.
• TRIP Clinic Santa Monica Physical clinic location at 20th Street & Arizona Avenue, Santa Monica serving West Los Angeles communities. Provides ketamine-assisted psychotherapy, clinical trials (including Usona psilocybin for MDD and Atai DMT for TRD), psychedelic integration, and psychotherapy services.
• Psilocybin Clinical Trials

Quantifiable outcome

• Studies show 50-70% of patients with treatment-resistant depression experience improvement after a series of ketamine treatments
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Atai Life SciencescoreStrategic or Co-development PartnerAtai Life Sciences is sponsoring PSI's Elumina VLS-01-203 DMT clinical trial for treatment-resistant depression. PSI serves as an enrolling research site for this study investigating short-acting DMT as a potential treatment for adults with TRD. The study involves 3 doses of investigational medicine or placebo over approximately 5 months with 15 visits.
• Usona InstitutecoreStrategic or Co-development PartnerUsona Institute is sponsoring PSI's uASPIRE PSIL301 psilocybin clinical trial for major depressive disorder at the Santa Monica TRIP Clinic. This Phase 3 study tests single oral doses of investigational psilocybin compared to placebo for adults with MDD, with up to 64 weeks of participation including potential for additional doses.
• Mind Medicine, Inc.coreStrategic or Co-development PartnerMindMed is sponsoring PSI's Panorama MM120-301 LSD clinical trial for generalized anxiety disorder at the Hollywood TRIP Clinic. This study evaluates MM120 (a LSD compound) for anxiety symptoms with approximately 56 weeks duration including a 40-week extension phase.
• CybincoreStrategic or Co-development PartnerCybin is referenced as a clinical trial sponsor alongside Atai, MindMed, and Usona Institute. PSI has participated in clinical trials sponsored by Cybin as part of its psychedelic research portfolio.
• Thank You LifeminorStrategic or Co-development PartnerThank You Life is a nonprofit partner on a mission to revolutionize mental healthcare and help eliminate financial barriers to psychedelic therapy. PSI accepts donations to its Community Access Fund through Thank You Life to make psychedelic-assisted therapy more accessible.
• Pacific Neuroscience Institute (PNI)coreStrategic or Co-development PartnerPSI officially launched on July 1, 2025, uniting Pacific Neuroscience Institute's TRIP Center (est. 2019) and California Center for Psychedelic Therapy (est. 2018). PNI, led by Dr. Daniel Kelly, has grown to 50+ clinicians across 11 Centers of Excellence within Providence Health with over $60M in philanthropy.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Innerwell: Virtual-first ketamine-assisted psychotherapy provider treating depression, anxiety and PTSD with tele-supported dosing. Comparable as a direct-to-consumer psychedelic therapy brand targeting treatment-resistant mental health conditions with subscription/pricing models similar to PSI's pay-as-you-go structure.
• Atai Life Sciences: Public clinical-phase biopharma sponsoring PSI's Elumina VLS-01 DMT trial for treatment-resistant depression. Direct peer as psychedelic compound developer partnered with PSI; comparable for trial-site selection and eventual commercial rollout of DMT-based therapy.
• Usona Institute: Nonprofit sponsoring PSI's uASPIRE PSIL301 psilocybin Phase 3 trial in MDD. Comparable as a psychedelic clinical-program sponsor reliant on sites like PSI to conduct pivotal research; same trial design and patient population as PSI's broader KAP clinical work.
• Mind Medicine (MindMed): Public biotech developing MM120 (LSD) for generalized anxiety disorder. PSI is an active clinical trial site for MindMed's Panorama MM120-301 study, directly comparable as a psychedelic clinical program operator with overlapping indication (GAD) and delivery via experienced clinician infrastructure.
• Numinus Wellness: Public psychedelic-assisted therapy operator with clinics in the US and Canada delivering ketamine therapy and psychedelic research services. Comparable as a multi-clinic psychedelic therapy platform with clinical trial capabilities overlapping PSI's KAP and integration model.

Regional players

• Cedar Psychiatry: Utah-based outpatient psychiatry and ketamine infusion clinic group with regional footprint in the Mountain West. Comparable as a multi-location psychiatric outpatient operator offering ketamine infusion services for treatment-resistant depression, though regional rather than directly overlapping PSI's LA market.

Broad incumbents

• Compass Pathways: Public biotech developing COMP360 psilocybin therapy with proprietary clinical infrastructure. Comparable because PSI runs Usona-sponsored psilocybin trials for MDD while operating KAP services; Compass represents the integrated drug+clinic model that PSI is positioned to feed as a clinical trial site.
• Field Trip Health (now Irwin Naturals / Field Trip): Former public psychedelic therapy clinic chain (Field Trip Health) operating ketamine clinics across the US before pivoting; comparable as a multi-clinic ketamine-assisted psychotherapy operator with similar treatment protocols, pricing model, and outpatient clinic format.

Emerging players

• Journey Clinical: Tech-enabled platform connecting patients to clinicians for ketamine-assisted psychotherapy with telehealth coordination. Comparable in psychedelic-assisted therapy delivery model and clinician network approach; emerging player building infrastructure parallel to PSI's brick-and-mortar TRIP Clinics.
• Cybin: Public psychedelic drug developer with CYB003 (psilocybin) and CYB004 (DMT) programs. PSI has trial experience with Cybin as a sponsor; comparable as an emerging psychedelic biopharma identifying sites like PSI for pivotal trials in depression and anxiety.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about California Center for Psychedelic Therapy